The company was founded in 2004 under the name Pharmalink AB and is based in Stockholm, Sweden.



Pharmalink changes name to Calliditas Therapeutics

Publication of results from Phase 2b study in The Lancet

End-of-Phase 2 meetings with FDA and EMA


Preparations for end-of-Phase 2 meetings with FDA and EMA

Obtains orphan designation for Nefecon in Europe

Invited to work with the Kidney Health Initiative (American Society of Nephrology) to identify surrogate endpoints in IgA nephropathy

Publication of meta-analysis related to change in urine protein as a surrogate endpoint with regards to IgA nephropathy, Tufts Medical Center, 2016


Receives financing from existing investors to progress clinical process towards Phase 3

Announces initial results from Phase 2b trial and achieves the primary endpoint in a planned interim analysis


Nefecon core patents are granted in the US, Europe, China and Hong Kong


Receives financing for completion of Phase 2b trial from Investinor and existing investors


Owners including Industrifonden and Bengt Julander finance the launch of the Phase 2b (NEFIGAN) trial


Pharmalink gains exclusive rights to the formulation technology to develop and manufacture Nefecon


Obtains US orphan designation for Nefecon


Phase 2a trial is completed, with positive results


Obtains access to TARGIT technology from West Pharmaceutical Services for specific delivery to ileocecal region

Stiftelsen Industrifonden invests in the company